美国 · 平台与数据 · MarketBeat
Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts
Odyssey Therapeutics (NASDAQ:ODTX) presented additional data from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative…
在 MarketBeat 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.marketbeat.com)


